Peter T Lansbury

Your health in the 21st century. A fix for faulty proteins.

Tom Fagan, Peter T Lansbury, 2005, Newsweek.

Genetics of Parkinson's disease and biochemical studies of implicated gene products.

Peter T Lansbury, P. Lansbury, A. Brice, 2002, Current opinion in cell biology.

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Peter T Lansbury, William Dauer, Ana Maria Cuervo, 2008, The Journal of clinical investigation.

Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation.

Peter T Lansbury, Robert H. Brown, P. Lansbury, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Jean-Christophe Rochet, Peter T Lansbury, P. Lansbury, 2004, Journal of molecular neuroscience : MN.

Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease.

Peter T Lansbury, P. Lansbury, June-Young Park, 2003, Biochemistry.

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Leonidas Stefanis, Peter T Lansbury, Ana Maria Cuervo, 2004, Science.

Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.

Gregory A Petsko, Dagmar Ringe, Chittaranjan Das, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity.

Peter T Lansbury, P. Lansbury, M. J. Volles, 2007, Journal of molecular biology.

Improving binding specificity of pharmacological chaperones that target mutant superoxide dismutase-1 linked to familial amyotrophic lateral sclerosis using computational methods.

Peter T Lansbury, P. Lansbury, S. Ray, 2010, Journal of medicinal chemistry.

Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.

Peter T Lansbury, P. Lansbury, H. Lashuel, 2003, Chemistry & biology.